UNSPSC 51111841: Cioteronel

This classification denotes an anti-androgen with the molecular formula C16H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1RTH95874Z, chemically known as 1,5-cis-verknupften but generally known as cioteronel, which bears US NIH Compound Identifier 55994. European Medicines Agency schedules Cioteronel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06319MIG. The term CIOTERONEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32).

UNSPSC 51111841 Cioteronel, a Commodity code, encompasses generic pharmaceutical products that state and local health systems, correctional facilities, and public welfare agencies procure through cooperative purchasing arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits manufacturers and distributors of generic multi-source pharmaceuticals and over-the-counter products for placement on statewide contracts serving participating state agencies and local government facilities across multiple states including Oregon. Work under this code involves supply of pharmaceuticals with certified compliance to current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), coordination with authorized wholesalers maintaining chargeback systems, and flexible pricing models including flat-price, net-price, and WAC-minus formats. Vendors must maintain substantial insurance coverage—$5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability—and demonstrate electronic data interchange capability for product ordering and reporting.

The most recent representative opportunity is MMCAP's Request for Proposal S1070000015802 for generic multi-source pharmaceuticals and OTC products, issued January 20, 2026, with proposals due March 26, 2026. MMCAP operates as a cooperative purchasing vehicle, meaning awarded contracts serve multiple participating jurisdictions rather than a single agency. The RFP does not identify specific set-aside designations or restrictions for disadvantaged enterprises. Evaluation weighs price competitiveness at 75 percent, with the remaining 25 percent divided among fixed pricing compliance, administrative fee-format data submission, EDI capability, and willingness to accept the 3 percent administrative fee. Contracts are effective July 1, 2026, with a two-year term for new vendors and optional extensions at MMCAP's discretion; incumbent vendors' amendments extend through June 30, 2028. Performance penalties of $200 to $1,500 per violation apply for late reporting, missed onboarding timelines, or improper class-of-trade denials.